The conference will take place at the Renaissance Suzhou Hotel, from 3-4 September. Image credit: Shutterstock/Erman Gunes

China’s rapid emergence as a global clinical trials powerhouse will be in sharp focus this September as leading voices from the biopharma and healthcare sectors convene in Suzhou for the launch of Outsourcing in Clinical Trials China and Clinical Trial Supply China.

Held over two days on 3-4 September 2025, the dual event brings together senior executives, regulators, and innovators across R&D, clinical operations, outsourcing, and supply chain to examine the evolving landscape of clinical development in China – arguably the world’s most dynamic biopharma market.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Strategic inflection point

China’s clinical trials sector has undergone significant structural transformation over the past five years, driven by a combination of regulatory shifts, capital inflows into biotech, and a shift toward more decentralised, patient-centric trial models. According to GlobalData analysis, China now surpasses the US for annual number of clinical trials.

Yet as the ecosystem expands, so too does its complexity – particularly in relation to cross-border compliance, data protection, and clinical logistics. This new industry event marks a pivotal moment, featuring an opening keynote panel on “The Evolving Clinical Trial Landscape in China: Challenges & Opportunities,” alongside in-depth discussions on artificial intelligence in drug discovery, clinical supply chain management, and geopolitical risk.

Sessions will span core operational challenges – including site selection, enhancing collaboration in outsourcing, comparator sourcing, cold chain logistics, and vendor management – as well as broader questions on global collaboration, clinical trial harmonisation, and China’s biotech ambitions.

The program includes a panel on “The Rise of Chinese Biotech: A Competitive Challenge for US Companies and Investors,” reflecting growing interest in China’s ability to scale R&D innovation, supported by state policy and venture capital.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

While China continues to make strides in drug discovery and innovation, integration into the global clinical development ecosystem remains uneven. Concerns around IP protection, regulatory uncertainty, and data localisation persist, particularly for international sponsors managing multi-country trials.

Speakers from IDA Ireland, Singapore’s Agency for Science, Technology and Research, and the US Maryland China Center will participate in a cross-border panel addressing the impact of China’s biotech boom on global trials.

On 4 September, delegates will have the opportunity to participate in a curated site visit to Biobay, the national biomedical innovation zone located in Suzhou Industrial Park. The tour includes direct engagement with local biotech executives and exposure to platform technologies shaping the next wave of drug development.

Confirmed speakers include:

  • Li Zeng, CEO, Jing Medicine
  • Summer Xia, CEO, Trial-Data Medicine
  • Vincent Zang, Senior Director, Clinical Trial Operation, Innovent Bio
  • Angela Yu, Head of Outsourcing, East China Pharm
  • Shen Xiao, CMO, Alebund
  • Siwei Li, Director, Drug Metabolism and Pharmacokinetics, Degron Therapeutics
  • Xiaoyu Deng, Founder, MDCE Medical
  • Megan Qin, Head of Medical Device Clinical Excellence Working Group, CMAC
  • Xiaoyu Deng, Founder, MDCE Medical
  • Claire Qin, Chief Strategy Officer,  Intelligen AI
  • Min Geng, Head of Supply Chain, Shanghai Pharma
  • Fiona Barry,  Editor in Chief & Director, Globaldata Healthcare
  • Shelly Xie，Associate Director, Clinical & QC Management,Eli Lilly
  • Jinna Qin, President, China Association for Vaccines
  • Daniel Gao, President, ISPE Supply Chain Committee
  • Xiaomei Wang, VP of Clinical Trial Operation, Key Therapharma
  • Yugang Ju, Head of Clinical Operation, Insilico Medicine
  • Quancheng Chen, Agency for Science, Technology and Research, Singapore
  • Chester Xiao, Head of Life Science Industry, IDA Ireland
  • Vikki Wang, Head of China Center, U.S. Maryland China Center

View the full list of speakers and the complete conference agenda here.

Don’t miss this exclusive opportunity to connect with industry leaders, gain actionable insights, and stay ahead in the rapidly evolving clinical trials landscape in China.

Join the Outsourcing in Clinical Trials China & Clinical Trial Supply China conference, happening 3-4 September at the Renaissance Suzhou Hotel.

Register here: https://hc.eventsonlineregister.com/tc-events/outsourcing-in-clinical-trials-clinical-trial-supply-china-2025/

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact